Minocycline reduces 3-month NIH Stroke Scale scores by 2.43 in acute ischemic strokeMinocycline may improve recovery for some patients after ischemic stroke

This meta-analysis evaluated the efficacy and safety of minocycline in patients presenting with acute stroke, including both ischemic and intracerebral hemorrhage. The study included a total population of 2186 patients. The primary objective was to assess changes in neurological status at 3 months post-stroke, specifically using the National Institutes of Health Stroke Scale (NIHSS) as the primary outcome measure. The study also evaluated several secondary outcomes related to functional independence, mortality, and physiological markers of stroke severity.

The intervention group received minocycline, while the comparator group received control or standard care. The analysis focused on the 3-month follow-up period to determine the impact of minocycline on neurological recovery. While the specific dosing protocols and administration routes for minocycline were not detailed, the analysis compared the outcomes of minocycline against standard care across the study population.

In patients with acute ischemic stroke, the primary outcome showed a significant improvement in 3-month NIH Stroke Scale scores. The results indicated a reduction in scores by 2.43 (95% CI -4.42 to -0.44; P = 0.0169). Additionally, a favorable signal was observed for functional independence, defined as a modified Rankin Scale score of 0 to 2, with an effect size of 1.40 (95% CI 1.05-1.86; P = 0.0219). However, the Barthel Index in ischemic stroke patients was reported as favored for minocycline but did not reach statistical significance.

In contrast, the results for patients with intracerebral hemorrhage did not show a significant change in 3-month NIH Stroke Scale scores. Furthermore, the secondary outcome of favorable outcomes (modified Rankin Scale 0 to 1) did not show significant improvement. Other secondary outcomes, including mortality, recurrent vascular events, hemorrhagic transformation, hematoma volume, perihematomal edema, and Matrix Metalloproteinase-9 levels, were not significantly altered in either patient group.

Regarding safety and tolerability, the data did not report specific adverse event rates, serious adverse events, or discontinuation rates. Consequently, the tolerability of minocycline in this specific population could not be quantified from the provided evidence. These findings regarding ischemic stroke outcomes may provide a point of comparison for other neuroprotective agents, though the specific evidence for minocycline in this context is currently characterized as low-certainty.

Several methodological limitations were identified in this meta-analysis, including substantial heterogeneity among the included studies and low-certainty evidence. Notably, the trial sequential analysis indicated that the evidence is currently insufficient to reach definitive clinical conclusions. These factors suggest that while the numerical reduction in NIHSS scores is statistically significant, the broader clinical application remains exploratory.

Clinically, minocycline may improve neurological recovery in acute ischemic stroke, but practitioners should interpret these findings as exploratory. The lack of significant improvement in intracerebral hemorrhage and the inconclusive trial sequential analysis suggest that more robust, homogeneous data are required before minocycline can be recommended as a standard of care. Questions remain regarding the optimal dosing, the specific mechanisms of action in ischemic versus hemorrhagic stroke, and the long-term safety profile of the medication in acute stroke management.